Immunogen Inc. buy melinda
Start price
09.08.18
/
50%
€8.07
Target price
30.08.18
€9.02
Performance (%)
12.63%
End price
30.08.18
€9.09
Summary
This prediction ended on 30.08.18 with a price of €9.09. The prediction had a final performance of 12.63%. melinda has a follow-up prediction for Immunogen Inc. where he still thinks Immunogen Inc. is a Buy. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Immunogen Inc. | - | - | - | - |
| iShares Core DAX® | -0.992% | -3.231% | 11.661% | 16.545% |
| iShares Nasdaq 100 | -0.225% | -3.339% | 36.491% | 43.334% |
| iShares Nikkei 225® | -0.736% | -7.859% | 18.597% | 4.253% |
| iShares S&P 500 | -0.509% | -2.979% | 26.341% | 40.911% |
Comments by melinda for this prediction
In the thread Immunogen Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 08/08 | 14:30 Présentatio
ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer.
Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779, and IMGN632.
The company was founded in March 1981 and is headquartered in Waltham, MA.
Nombre d'employés : 293 personnes.